DeliDAPA
Description:
DeliDAPA contains Dapagliflozin 5 mg. Dapagliflozin is used for the management of type 2 diabetes mellitus. It belongs to sodium-glucose co-transporter 2 (SGLT2) inhibitors class of drugs. These medications work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. Dapagliflozin is typically prescribed as an adjunct to diet and exercise to help improve glycemic control in individuals with type 2 diabetes.
Category: Renal Medicine
Indications
Dapagliflozin is indicated:
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors
- To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction.
Composition:
Each tablet of DeliDAPA contains Dapagliflozin 10 mg
Mechanism of action:
Dapagliflozin is a highly potent, selective, and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that improves glycemic control in patients with type 2 diabetes mellitus by reducing renal glucose reabsorption leading to urinary excretion of excess glucose (glucuresis). DeliDAPA is available as oral tablets and requires once-daily dosing.
Purpose
- In adults aged 18 years and older with type II diabetic mellitus to improve glycemic control.
- As mono-therapy when diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
- As add on combination therapy in combination with other glucose–lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control.
Dosage:
Dapagliflozin is administered orally. The recommended dose is 10mg once daily. Tablets are to be swallowed whole at any time of day with or without food. There is no dose adjustment required for patients with renal impairment. Treatment should not be initiated in patients with severe renal impairment (GFR <30>
Presentation:
One carton contains 10 strips of 10 tablets each.
